While TGFb plays a critical role in tumor formation and progression, the role and contribution of its three different isoforms remain unclear. In this study, we aimed at elucidating the prognostic value of the TGFb isoforms and assessed their expression levels in breast cancer patients at different stages of the disease. We found higher levels of TGFb1 and TGFb3 in cancer patients compared to normal tissues, with no significant changes in TGFb2 expression. Similarly, TGFb1 and TGFb3, but not TGFb2, showed higher expression levels in advanced lymph node-positive and metastatic tumors, suggesting different roles for the different isoforms in tumor progression and the metastatic process, while in the least aggressive molecular subtype (luminal A), expression of the three TGFb isoforms significantly correlated with expression of both TGFb receptors, such correlation only occurred between TGFb1 and TGFb3 and the TGFb type II receptor (TbRII) in the highly aggressive basal-like subtype. Interestingly, a distinct and somehow opposite pattern was observed in HER-2 tumors, only showing significant association pattern between TGFb2 and the TGFb type I receptor (TbRI). Finally, the three TGFb isoforms showed distinct association patterns with patient outcome depending on the different molecular subtype, highlighting context-dependent, differential prognostic values.
Introduction
The transforming growth factor b (TGFb) growth factors are expressed in most of the tissues and orchestrate various physiological processes including hormonal and immune responses, tissue repair, cell growth, cell death, cell fate determination, among others. 1, 2 The TGFb family comprises three isoforms TGFb1, TGFb2, and TGFb3, each encoded by a different gene. Despite the fact that the three isoforms show structural similarities 3 and usually transduce their signals through the same signaling pathways, 4, 5 they also exhibit tissue-specific expression and have different affinities for TGFb receptors. 6, 7 Interestingly, the three TGFb isoforms also have distinct expression patterns and functions during normal mammary gland development. TGFb1 expression is high in the mammary tissue of virgin and early pregnant mice, reduced during pregnancy, and up again after weaning. 8, 9 In contrast, TGFb2 was found to be low in the mammary glands of virgin mice, gradually increased through pregnancy, and decreased during lactation. TGFb3 expression is also increased during pregnancy, reaching maximum levels before parturition, and start falling during lactation before peaking again after weaning. 8, 10 This difference in the expression levels observed during the mammary cycle was also associated with some difference in the expression patterns of the three isoforms during alveolar morphogenesis. 11 For example, in contrast to both TGFb1 and TGFb2, TGFb3 was shown to be more expressed in the ducts than the alveoli. 11 In addition, the function of each isoform was found to be distinct. TGFb1 plays a role in different biological processes including cell growth, differentiation and epithelial-mesenchymal transition (EMT), 12 ductal development and epithelial proliferation, matrix remodeling, apoptosis, and suppression of ovarian hormones' proliferative effects. 13, 14 TGFb2 is involved in epithelial-stromal cross-talk and matrix remodeling. 11 In contrast, TGFb3 has a role in the maturation of myoepithelium, suppression of milk secretion, 15 and the EMT process. 16, 17 In cancer, the three isoforms also play different functions. For example, TGFb1 is well known for its role in cell motility, invasion, and metastasis and in promoting EMT process. 1, [18] [19] [20] [21] [22] [23] In contrast, TGFb2 was suggested to play a role in enhancing tumor proliferation and decreasing immune surveillance during tumor development. 24 However, TGFb3 was proposed to play a role in the EMT process. 16, 17 Furthermore, recent reports suggested that different TGFb isoforms might exert distinct functions in skin cancer tumorigenesis, according to tumor advancement and stage. 25 In breast cancer, TGFb has a dual role ranging from a tumor suppressor function to an oncogenic role, depending on cell type and stage of the disease. 1 The mechanisms involved in this transition are still not fully understood. 1, 20, 21, [26] [27] [28] [29] [30] [31] [32] Notably, most studies on the role of TGFb in cancer formation and progression were performed using TGFb1 and few information is available with respect to the other isoforms in these processes. Previous report showed variable levels of TGFb isoforms in the different breast cancer tumors. However, due to the limited number of cases examined, no detailed analysis was performed to evaluate the association between the expression of the different isoforms and clinicopathological parameters. 33 Another recent study showed a preferential expression of the different isoforms in malignant and premalignant breast cancer lesions compared to normal tissues. 34 These studies suggest different roles for the three TGFb isoforms in the pathogenesis of the disease.
Thus, and considering the prominent role played by the TGFb family in breast cancer formation and progression, it is important to decipher the specific functions and pattern of expression of each TGFb isoforms in breast cancer. Indeed, further clarifying the role of TGFb in tumorigenesis and our understanding of the molecular mechanisms underlying tumor formation and progression may prove useful for designing more specific and efficient therapeutic strategies. In this study, we analyzed the expression patterns of the three TGFb isoforms in the different breast cancer molecular subtypes and their association patterns with different clinical and pathological features, using tissue samples, tissue microarrays (TMAs) as well as publicly available datasets on large cohorts of breast cancer patients. Furthermore, we also investigated and correlated the TGFb isoform expression patterns with those of the TGFb type I and type II receptors (TbRI and TbRII) as well as with the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2) status of the tumors. Interestingly, our results indicate that breast cancer tissues show higher TGFb1 and TGFb3 levels compared to normal tissues. Moreover, we also found increased TGFb1 and TGFb3 and decreased TGFb2 expression in advanced lymph node (LN)-positive and metastatic tumors. Our data also indicate that the different TGFb isoforms have distinct patterns of co-expression with the TGFb receptors, depending on the breast cancer molecular subtypes. In addition, our results also indicate that the prognostic values of each isoform vary and sometimes were opposite to each other according to the molecular subtypes.
In summary, our results define differential and distinct expression patterns for the different TGFb isoforms according to the stage of tumor progression and the molecular subtype. These results strongly suggest that the different isoforms play distinct roles and have different functions in different stages of the disease and in the different molecular subtypes of breast cancer. A better understanding of their specific roles and functions should prove useful in establishing more specific therapeutic options by targeting specific isoforms in distinct molecular subtypes, which in turn will contribute to better and improved patient response and outcome.
Results

All TGFb isoforms are essential for breast cancer tumorigenesis
Most studies on the role of TGFb in breast cancer were performed using the TGFb1 isoform. To start evaluating the effect of different TGFb isoforms in breast carcinogenesis, we first analyzed their tumor initiating capacities using tumorsphere assay in the basal subtype breast cancer cell line (SUM159) as previously described. 22, 23 As shown in Figure 1 , all TGFb isoforms could significantly increase the number of cancer stem cells, as measured by the increased sphere-forming ability of these cells when stimulated by TGFb1, TGFb2, and TGFb3. These effects were observed and quantified on both tumorsphere numbers (Figure 1(b) ) and tumorsphere sizes (Figure 1(c) ). The effects appear specific to the TGFb family, as Activin A, a closely related TGFb family member, 35 does not induce any change in tumorsphere size or numbers (Figure 1 ). These data further confirm the important and specific role played by TGFb in regulating breast tumorigenesis and indicate that all isoforms are active in this process.
TGFb1 and TGFb3, but not TGFb2, expression levels are increased in breast cancer compared to normal tissues
We next compared the three TGFb isoform expression levels in malignant cases versus normal tissues using The Cancer Genome Atlas (TCGA) datasets of the large publicly available ONCOMINE database. As shown in Figure 2 (a), we found a significant increase in TGFb1 (1.630 fold; p = 2.30E214) and TGFb3 (1.5 fold; p = 4.61E26) gene expression levels in malignant tissues (389 breast cancer patients) compared to their normal counterpart (61 normal breast tissues). In contrast, no detectable change in expression was observed for TGFb2. These data highlight a selective upregulation of specific TGFb isoforms, namely, TGFb1 and TGFb3, in breast cancer, suggesting a differential role for the different isoforms in breast cancer tumorigenesis.
Advanced LN-positive and metastatic tumors are associated with higher TGFb1 and TGFb3 and lower TGFb2 messenger RNA levels
To further evaluate the prognostic role of the different TGFb isoforms in breast cancer and their role in tumor progression, we next assessed the association between their expression levels and tumor size, LN status, and the presence or absence of distance metastasis, using large datasets of the ONCOMINE database. While TGFb1 messenger RNA (mRNA) levels were significantly higher in larger size tumor (T2, T3, and T4) compared to T1, TGFb2 mRNA was significantly reduced in larger tumors compared to T1. In contrast, TGFb3 showed no distinct pattern compared with size ( Figure 2(b) ). Moreover, and due to the fact that TGFb also plays a critical role in promoting breast cancer invasion and metastasis, we next evaluated the association between expression of the different TGFb isoforms and LN involvement as well as distant metastasis. Interestingly, higher mRNA expression levels of both TGFb1 and TGFb3 were observed in both LNpositive and metastatic tumors (Figure 2 
TGFb isoforms and their association with classical breast cancer markers
For breast cancer, expression of the classical biomarkers, including ER, PR, and HER-2 status, has an important clinical and prognostic value. Thus, we evaluated the association between TGFb isoforms and the ER, PR, and HER-2 status of the tumors. Our analysis revealed that TGFb1 and TGFb3 mRNA expression levels were higher in ER-positive and/or PR-positive tumors compared to ER-and/or PR-negative tumors. TGFb2 expression, however, was higher in the ER-negative tumors (p \ 0.0001; Figure 3 Breast cancer subtypes showed differential expression of TGFb isoforms with more expression of TGFb1 and TGFb2 in the highly aggressive triple-negative breast cancer tumors
The different breast cancer molecular subtypes have distinct prognostic and predictive markers and values. 36 We assessed mRNA expression levels of the different TGFb isoforms in 1881 breast cancer cases, using the GOBO database and Hu classification method. 37 We found higher TGFb1 and TGFb2 mRNA levels in basal tumors compared to other molecular subtypes (p 0.00001; Figure 4 (a) and 4(b)). TGFb3, however, showed a different expression pattern with the highest expression levels found in the luminal A tumors and the least expression in the basal-like subtype ( Figure  4(c) ). These results indicate that TGFb isoforms are expressed at variable levels in the different molecular subtypes, suggestive of differential roles played by the different isoforms in the pathogenesis of the distinct molecular subtypes.
TGFb ligand and receptor expression patterns are molecular subtype-specific
We next analyzed whether expression of the TGFb isoforms could correlate with the expression of the two TGFb signaling receptors (TbRI and TbRII). Using the Breast Cancer Gene-Expression Miner v4.0 in a cohort of 5260 breast cancer patients, we found TGFb1 mRNA levels to significantly correlate with TbRII mRNA expression (r = 0.17, p \ 0.0001), while showing no association with TbRI mRNA expression (r = 0.01, p = 0.27). In contrast, we found TGFb2 and TGFb3 expression to be significantly associated with TbRI expression (r = Figure 5(a) and (b) ).
We next more specifically investigated whether the observed association between the different isoforms and their receptors varied depending on the breast cancer subtypes, using the Breast Cancer Gene-Expression Miner v4.0 correlation tool. Interestingly, the association between expression levels of TGFb1 and TbRII, observed in Figure 5 (a), was found to be specific to the basal-like subtype ( Figure 5(c)) . A similar and significant association was also found between the TGFb3 isoform and TbRII. However, the association between expression of TGFb2 and TbRI could only be found in the HER-2 subtype. No clear or significant association could be established in the luminal subtypes, no matter the isoform (Figure 5(c) ).
In summary, aggressive basal-like tumors showed significant correlation between TGFb1 and TGFb3 with TbRII, while HER-2 tumors only show significant correlation between TGFb2 and TbRI. Altogether, these data highlight the complex network association between TGFb ligands and their receptors, in a specific molecular subtype-dependent manner and further support the notion that TGFb1 and TGFb3 exhibit a different functional behavior compared to TGFb2 in breast cancer progression and aggressiveness. These specific patterns of association between the TGFb isoforms and their receptor may prove useful for the detection/prediction of specific subtypes of breast tumors.
TGFb1 and TGFb3, but not TGFb2, are significantly associated with endoglin in highly invasive breast cancer tumors Endoglin (CD105) is a TGFb co-receptor and is found to be highly expressed in endothelial cells. 38 Moreover, endoglin expression was found to be increased in solid tumors and its expression in malignant cells increased their invasive capacity and migration potentials. 38 Interestingly, while endoglin has a constant affinity for both TGFb1 and TGFb3, it has a weak affinity for TGFb2. 6 Thus, to further evaluate the role of each isoforms in breast cancer angiogenesis, invasion, and metastasis, we examined the association of each isoform with endoglin. In addition, analysis of a large cohort of breast cancer patients (over 5000 patients) revealed a strong association between endoglin and TGFb1 and TGFb3 (r = 0.2 and r = 0.14) while showing a weaker association with TGFb2 (r = 0.08; Figure  5(d) ). Moreover, patients diagnosed with the most aggressive basal-like subtypes showed a strong positive association between endoglin and TGFb1 (r = 0.38) and endoglin and TGFb3 (r = 0.30; Figure 5(e) ). In contrast, no association was found between endoglin and TGFb2 (r = 0.03) in this highly aggressive breast cancer subtype ( Figure 5(e) ).
These results further emphasize the strong association between expression of TGFb1 and TGFb3 with tumor progression and aggressiveness and also suggest that TGFb2 may exert a different role during these processes. These also highlight the need for developing more specific therapeutic options that may specifically affect one or the other TGFb isoforms.
TGFb1 protein expression is upregulated in breast cancer cases compared to normal tissue and correlates with advanced-stage, larger size tumor, and LN-positive tumors
To further confirm our findings, we next evaluated the protein expression level of TGFb1, the most abundant isoform in most tissues, using a TMA composed of 102 breast cancer cases. Our results showed a significantly higher TGFb1 expression in invasive breast cancer cases (71%) compared to (20%) normal/benign and (17%) in situ carcinoma (Figure 6(a) and (b) ). Next, and to further evaluate the role of TGFb1 in breast cancer tumor progression, we investigated the association between TGFb1 protein expression and tumor grade, size, LN status, and stage ( Figure 6(a) ). While TGFb1 showed no significant difference with tumor grade, its expression was significantly increased (72%) in larger size tumors (.2 cm) compared to smaller size tumors (17%) and LN-positive tumors (73%) compared to LN-negative (62%) tumors. In addition, TGFb1 was significantly higher (70.7%) in the more advanced stages II and III compared to earlier stages (17%; stages 0 and I).
Due to the important role of the ER, PR, and HER-2 status in determining patient prognosis and therapeutic options, we also evaluated the association between TGFb1 protein levels and ER, PR, and HER-2 status (Table 1) . While TGFb1 protein expression levels did not vary according to ER and HER-2 status, a clear association trend was observed with PR expression (Table 1) .
We also assessed the TGFb1 expression levels in association with different molecular subtypes using the previously described classification method. 39, 40 As shown in Table 1 , TGFb1 highest expression was observed in the highly aggressive triple-negative breast cancer (TNBC) subtype (74%), while at the lowest in HER-2 (68%) and luminal B (47%) subtypes. Moreover, our immunohistochemistry (IHC) data in breast tumors revealed stronger association between TGFb1 with TbRII, compared to TGFb1 and TbRI expression (Table 1) . Together, these data highlight the strong association between TGFb1/ TbRII axis and aggressive breast cancer tumors and further define TGFb1 as a marker of tumor progression, LN involvement, metastasis, and aggressive phenotype in breast cancer.
Discussion
In breast cancer, TGFb exerts a complex role acting as a tumor suppressor in early breast carcinogenesis while promoting tumor progression, EMT, and metastasis in more advanced breast cancers. 1, 20, 21, [26] [27] [28] [29] [30] [31] [32] This complexity was also observed with respect to the prognostic value of TGFb receptors, which also display a dual prognostic role, depending on disease progression and molecular subtype. 39 This could be in part attributed not only to breast cancer heterogeneity but also to the fact the TGFb family comprises more than one ligand. The three TGFb isoforms have different tissue-specific expression and are encoded by distinct genes. 6, 7 Their specific and distinctive biological functions and prognostic values have not been addressed yet. TGFb1 is the most abundant isoform and plays different physiological roles, including an important role in inducing and promoting EMT, cell motility, invasion, angiogenesis, metastasis, and stemness. [18] [19] [20] [21] [22] [23] In contrast, TGFb2 was shown to play a role in reducing immune surveillance of tumor development and enhancing tumor growth. 24 TGFb3 was shown to play a role in the morphogenesis of lung and normal palate and to regulate epithelial-mesenchymal interaction suggesting a role in the EMT process in cancer. 16, 17 Figure 5. TGFb1, TGFb2, and TGFb3 mRNA levels and its association with TbRII and TbRI and endoglin mRNA levels in different breast cancer subtypes. (a) TGFb1, TGFb2, and TGFb3 mRNA levels and their association with TbRII mRNA levels in around 5000 human tumor samples using bc-GenExMiner 4.0 database. (b) TGFb1, TGFb2, and TGFb3 mRNA levels and their association with TbRI mRNA levels in around 5000 human tumor samples using bc-GenExMiner 4.0 database. (c) Correlation between different TGFb isoforms in addition to TbRII and TbRI mRNA levels in different breast cancer subtypes using bc-GenExMiner 4.0 database. (d) TGFb1, TGFb2, and TGFb3 mRNA levels and their association with endoglin mRNA levels in around 5000 human tumor samples using bc-GenExMiner 4.0 database. (e) TGFb1, TGFb2, and TGFb3 mRNA levels and their association with endoglin mRNA levels in 580 basal-like breast cancer subtypes using bc-GenExMiner 4.0 database.
In normal mammary development, it was shown that different TGFb isoforms are expressed differentially during the different phases of development of the mammary gland. 8 Interestingly, while TGFb1 was shown to be reduced during pregnancy, TGFb2 and TGFb3 were found to be upregulated during pregnancy. 8 These indicate that the TGFb isoforms may play different roles during mammary gland development and during breast cancer formation and progression. In this study, we analyzed the expression levels of the TGFb isoforms alone or in combination with their receptors in large cohorts of breast cancer patients, as well as in normal, benign, in situ, and invasive breast carcinoma of different grades and stages. Interestingly, we found TGFb1 and TGFb3, but not TGFb2, to be expressed at higher levels in invasive breast cancer compared to normal tissues. These findings are in agreement with recent reports showing differential expression of the three isoforms in breast cancer 34 and in malignant grades of HaCaT keratinocytes. 25 Further analysis revealed that only TGFb1 and TGFb3 expression levels are higher in bigger size, LN-positive, and metastatic tumors. In contrast, TGFb2 expression correlates with smaller tumor size, LN-negative tumors, and tumors with no distant metastasis. This is indicative of different functions played by the TGFb isoforms in breast cancer tumorigenesis and of a differential behavior between the two groups (TGFb1 and TGFb3 vs TGFb2) in association with disease progression. Our results also suggest that the two groups may have opposing role in the advanced-stage tumor compared to early tumors, thereby accounting in part for the dual role of TGFb pathway in breast carcinogenesis.
Due to the heterogeneous nature of the breast cancer disease, we also evaluated the expression levels of the TGFb isoforms and receptors in the different molecular breast cancer subtypes. Our results revealed expression correlations between TGFb1 and TGFb3 and the type II TGFb receptor (TbRII) in the most aggressive basallike breast tumors. In addition, both TGFb1 and TGFb3 were also strongly associated with endoglin, which is highly expressed in activated endothelium of tumor vessels and known to play a role in vascular invasion, further highlighting the prominent role for TGFb1 and TGFb3 in the promotion of breast cancer invasion. Interestingly, the HER-2-enriched subtype showed a complete different pattern of association between the different isoforms and the receptors, showing only a significant association between TGFb2 and TbRI. This suggests a different TGFb signaling interplay between the two most invasive breast cancer molecular subtypes (HER-2 and basal) and may help define more precise therapeutic strategies based on targeting specific TGFb isoforms in specific breast cancer subtypes. Moreover, while TGFb1 and TGFb3 are expressed at higher levels in LN-positive and metastatic tumors, TGFb2 levels are lower in these advanced, invasive tumors, raising the appealing hypothesis of having opposing roles played by the different isoforms in regulating breast cancer progression and metastasis.
Our results also highlight a distinct association between the different TGFb isoform and the classical breast cancer biomarkers (ER, PR, and HER-2). This suggests potential differential roles for each of the isoforms in modulating the classical biomarkers' expression. Thus, this work will provide an interesting experimental starting point for future studies to specially address the role of the different isoforms.
In summary, while we found all three TGFb isoforms to be expressed and biologically active in breast cancer, we also showed that they exhibit differential expression as well as specific co-expression with their receptors. These distinct expression patterns may, in turn, dictate different roles, prognosis values, and disease outcomes between the isoforms, according to the stage, grade, metastatic status, and molecular type of the disease. Further investigation of the precise role and function of these isoforms in the different molecular subtypes will help refine more precise therapeutic options by targeting specific isoforms in a subtypespecific manner and lead to improved patient response and outcome. and Ki67 expression and status, the cases were reclassified according to molecular subtypes as described. 40 
IHC
The slides were first baked at 55°C for 30 min. This was followed by deparafinization in xylene and rehydration in 100%, 95%, 70%, and 50% ethanol and by heatinduced antigen retrieval in sodium citrate 10 mM, pH 6.0 buffer. This was further followed by hydrogen peroxide block incubation for 10 min and Ultra V Block. TGFb antibody was added and incubated for 1 h at room temperature, and then, UltraVision LP Detection System HRP Polymer and DAB Plus Chromogen (Thermo Fisher Scientific, Fremont, CA, USA) were added. The slides were then scanned using Aperio XT slide scanner (Leica Biosystems, Concord, ON, Canada) and analyzed by an experienced pathologist.
IHC scoring
ER and PR were scored according to Allred scoring system, while HER-2 expression was classified according to ASCO/College of American Pathologists Guidelines for HER-2 testing in breast cancer. Ki67 cases were considered positive if they scored 14% or more and negative if less than 14%. TGFb1 was scored in a semiquantitative method with a score of 0 indicating undetectable expression, +1 if 1%-20% of tumor cells were positively stained, and +2 if .20% of tumor cells were positive. Both scores 0 and +1 was considered as negative, while +2 score was considered positive. The slides were scored independently by two investigators.
Data mining
Different large publicly available databases include ONCOMINE, GOBO, and Breast Cancer GeneExpression Miner database. TCGA dataset of ON COMINE database which includes 398 invasive breast cancer cases and 61 normal breast cancer tissues was used to investigate the difference in TGFb isoform expression between normal and invasive breast cancer tumors. In addition, Sorlie dataset was also used to investigate the correlation between TGFb mRNA levels and tumor size. Gene expression of the three TGFb isoforms in different molecular subtypes of breast cancer was evaluated using GOBO database which include data of more than 1881 breast cancer patients. Finally, Breast Cancer Gene-Expression Miner v4.0 (bcGenExMiner v4.0) online dataset (http:// bcgenex.centregauducheau.fr) comprising previously published gene expression datasets from 15 independent breast cancer studies totaling 2413 tumors was used to evaluate the association between different isoform expression and patients' outcome. All experimental protocols and procedures were performed in accordance to McGill University regulations. All experimental protocols and procedures were approved by McGill University.
Author contributions
Mahmood Y Hachim and Ibrahim Y Hachim performed experiments, bioinformatic analysis, and drafting of the article. Meiou Dai performed experiments. Suhad Ali contributed to the experimental design and corrections of the article. Jean-Jacques Lebrun is the principal investigator who initiated the research design and supervision of the project and writing of the article.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grants from the Canadian Institutes for Health Research (CIHR to J.-J.L.).
